Kendle International Inc

Kendle International — Investor Presentation (May 2005)

20 slides from Kendle International's investor presentation, May 31, 2005

  1. Slide 1: Corporate Overview: Kendle on the move

    CORPORATE OVERVIEW Kendle on the move

  2. Slide 2: Slide 2

  3. Slide 3: Kendle is among the world's leading global clinical research organizations

    Kendle (Nasdaq: KNDL) is among the world’s leading global clinical research organizations. We deliver innovative and robust clinical development solutions — from first-in-human studies through market launch and surveillance — to help the world’s biopharmaceutical companies maximize product life cycl

  4. Slide 4: Kendle Clinical Development

    Kendle Clinical Development The global drug development environment is changing More rigorous testing in response to growing regulatory and legal pressures, increased outsourcing penetration and a broader market are all factors combining to create significant growth opportunities for CROs. Analysts

  5. Slide 5: Global patient access and project delivery

    Rea Global patient access and project delivery Patient access is among the key challenges to delivery of global Phase III programs for our customers. To meet this challenge, we have established capabilities in most major markets around the world. Our focus has been to increase our presence in emergi

  6. Slide 6: Kendle Clinical Development: Leadership that delivers

    NDLE CLINICAL DEVELOPMEN Leadership that delivers Focused on the future Our dedicated project teams are headed by project leaders who manage and coordinate the activities of their multifunctional gobal team. The teams - comprised of clinical research associates, safety specialists, data managers, bi

  7. Slide 7: Delivering complex multi-continental studies

    North America Delivering complex multi-continental studies In 2004, Kendle was contracted to conduct a complex pediatric study for a major biopharmaceutical company with operations in North America, Europe and Australia. The study is being conducted across six countries in Europe as well as the Unit

  8. Slide 8: Kendle Regulatory Affairs

    Kendle Regulatory Affairs

  9. Slide 9: Safety first

    Safety first a Kendle The timely collection, analysis and accurate reporting of drug safety data from clinical studies and marketed products are regulatory requirements and a vital strategic need. It’s likely that drug safety will continue to drive strong political activism in the form of legislatio

  10. Slide 10: Kendle Regulatory Affairs: Focused on the future

    KENDLE REGUL RY AFFAIRS Focused on the future Kendle is strongly positioned to establish a leadership position in the regulatory affairs industry, in particular in the areas of safety and pharmacovigilance. The future is all about electronic safety reporting to regulatory agencies and Kendle is at t

  11. Slide 11: Regulatory consulting for Indian biopharmaceutical clients

    Abhay Muthal PhD, Deputy General Manager, Regulatory Affairs, Sun Pharmaceutical Industries Led. Kendle’s Regulatory Consulting and Submissions Group in Rockville, Maryland, has active clients in India and serves as the U.S, Agent for a number of these firms for their Drug Master Files, Abbreviated

  12. Slide 12: Kendle Biometrics

    Kendle Biometrics

  13. Slide 13: The Kendle advantage

    The Kendle advantage Continued success North America We utilize a global network to deliver the highest quality data and maximize operating efficiencies. Our global data centers are in close proximity to high-enrolling sites and include offices in the United States, Europe, Australia and Mexico. Our

  14. Slide 14: Kendle Biometrics: Focused on the future

    ENDLE BIOMETRICS Focused on the future In today’s market environment, biopharmaceutical companies need to accelerate the clinical development process to get their drugs to market faster than the competition without increasing costs. To do this it’s vital to identify critical variables early on and c

  15. Slide 15: Customizing solutions

    Customizing solutions Top 20 Biopharmaceutical Company A top 20 biopharmaceutical customer was in the midst of a Phase Ill critical path trial in preparation for a new drug application submission. The company had collected a mountain of data that needed to be cleaned to complete its analysis. A sudd

  16. Slide 16: Kendle Late Phase

    Kendle Late Phase

  17. Slide 17: The Kendle advantage

    The Kendle advantage North America Most recently, heightened concerns over the safety of approved and widely prescribed Cox 2 drugs have raised calls for more thorough testing and increased long-term safety surveillance. The recent establishment of the Drug Safety Oversight Board within the FDA, the

  18. Slide 18: Kendle Late Phase: Focused on the future

    ENDLE LATE PHASE Focused on the future We'll continue to build our Phase IIIB/IV, health economics and outcomes research, and scientific events, education and publications business globally, expanding our capabilities to meet the needs of our customers. We'll also focus on growing our share of large

  19. Slide 19: Keeping ahead of schedule

    North America Keeping ahead of schedule Kendle completed a Phase IV trial in 2004 for a major pharmaceutical company and marketer of a leading non- prescription pain reliever under a preferred provider relationship with this organization’s parent company. The trial studied the effectiveness of a low

  20. Slide 20: Real people. Real results.

    Real people. Real results.” Kendle Corporate Headquarters 1200 Carew Tower, 441 Vine Street, Cincinnati OH 45202 Tel: 513 381 5550 Fax: 513 381 5870 REGIONAL CONTACT CENTERS UK/Europe: Crowthorne, Berkshire, UK. Tel: +44 1344 750 225 Asia/Pacific: Melbourne, Australia. Tel: +61 3 9567 7600 Latin Ame

Kendle International — Investor Presentation (May 2005) on 6ix